Combination therapy for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding an experimental drug (rSIFN-co) to the standard total neoadjuvant therapy (TNT, which is chemotherapy and radiation given before surgery) for patients with mid-low rectal cancer that hasn't spread. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and have a body mass index (BMI) of 17 or higher (a measure of weight relative to height).
- You must have rectal cancer located within 12 cm (about 5 inches) from the anal verge, and it must be a type called pMMR/MSS, which means it has a certain genetic marker.
- Your cancer stage must be T3, T1-2 with lymph node involvement, or T4, and it must not have spread to distant organs (M0).
- You must be able to care for yourself (ECOG 0-2) and be expected to live at least 6 more months.
- You must have adequate organ function, including normal blood counts, liver and kidney function.
- You must agree to use effective birth control during the study and for a period after (6 months for women, 3 months for men).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests a new approach for people with high-risk rectal cancer that has not spread. It combines short-course radiation with a four-drug chemotherapy and an immunotherapy drug before surgery, aiming to shrink the tumor and improve outcomes.
This trial tests a new combination of chemotherapy, radiation, and an immunotherapy drug called tislelizumab before surgery for rectal cancer that has grown locally. The goal is to see if this approach can shrink the tumor more effectively and improve surgical outcomes.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Hear when a new Mid-low Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.